BioTime, Heraeus Medical deal

BioTime’s OrthoCyte Corp. subsidiary and Heraeus granted each other rights to their respective technologies to develop and commercialize a cell therapy bone grafting product based on BioTime’s PureStem human embryonic progenitor cell technology, and either BioTime’s HyStem scaffold technology or Heraeus’ scaffold technology. BioTime’s license to Heraeus is for exclusive, worldwide rights to develop and commercialize the cell therapy product for all osteoskelton diseases and injuries, except oral maxilla-facial, using HyStem. ...